2556646-63-8
2556646-63-8
Chemical Structure
Visugromab
Synonym(s): CTL-002
- CAS No.: 2556646-63-8
- Formula:N/A
- Molecular Weight:(144.56 kDa)
IUPAC Name: (E)-N,5-bis(4-chlorophenyl)-3-((propan-2-yl-d7)imino)-3,5-dihydrophenazin-2-amine
SMILES: [Visugromab]
Biological Activity: Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Visugromab | 98.40% | Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Visugromab (Powder) | Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
